Prague Med. Rep. 2024, 125, 101-129

https://doi.org/10.14712/23362936.2024.10

Evidence for Therapeutic Drug Monitoring of Atypical Antipsychotics

Veronika Krejčí1,2, Irena Murínová1,3, Ondřej Slanař2, Martin Šíma2

1Department of Clinical Pharmacy, Military University Hospital Prague, Prague, Czech Republic
2Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
3Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic

Received January 30, 2024
Accepted May 7, 2024

References

1. Agid, O., Mamo, D. C., Ginovart, N., Vitcu, I., Wilson, A. A., Zipursky, R. B., Kapur, S. (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response – A double-blind PET study in schizophrenia. Neuropsychopharmacology 32(6), 1209–1215. <https://doi.org/10.1038/sj.npp.1301242>
2. Aichhorn, W., Marksteiner, J., Walch, T., Zernig, G., Saria, A., Kemmler, G. (2006) Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int. Clin. Psychopharmacol. 21(2), 81–85. <https://doi.org/10.1097/01.yic.0000188213.46667.f1>
3. Arakawa, R., Ito, H., Takano, A., Takahashi, H., Morimoto, T., Sassa, T., Ohta, K., Kato, M., Okubo, Y., Suhara, T. (2008) Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl.) 197(2), 229–235. <https://doi.org/10.1007/s00213-007-1029-z>
4. Aravagiri, M., Marder, S. R., Nuechterlein, K. H., Gitlin, M. (2003) Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther. Drug Monit. 25(6), 657–664. <https://doi.org/10.1097/00007691-200312000-00003>
5. Aripiprazole (2009) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/documents/product-information/abilify-epar-product-information_en.pdf (Accessed January 6, 2024)
6. Attarbaschi, T., Sacher, J., Geiss-Granadia, T., Klein, N., Mossaheb, N., Lanzenberger, R., Asenbaum, S., Dudczak, R., Kasper, S., Tauscher, J. (2007) Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. Eur. Neuropsychopharmacol. 17(2), 102–107. <https://doi.org/10.1016/j.euroneuro.2006.07.001>
7. Bachmann, C., Rieger-Gies, A., Heinzel-Gutenbrunner, M., Hiemke, C., Remschmidt, H., Theisen, F. (2008) Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther. Drug Monit. 30(4), 462–466. <https://doi.org/10.1097/FTD.0b013e318178e18d>
8. Baldelli, S., Cheli, S., Montrasio, C., Cattaneo, D., Clementi, E. (2021) Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience. World J. Biol. Psychiatry 22(1), 34–45. <https://doi.org/10.1080/15622975.2020.1747112>
9. Bergemann, N., Frick, A., Parzer, P., Kopitz, J. (2004) Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 37(2), 63–68.
10. Bhavsar, N., Dopheide, J. A., Botello, T., Wang, M. (2024) Therapeutic drug level monitoring of antipsychotics at an inpatient psychiatric hospital. Ther. Drug Monit. 46(2), 210–216. <https://doi.org/10.1097/FTD.0000000000001156>
11. Brexpiprazole (2018) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/documents/product-information/rxulti-epar-product-information_en.pdf (Accessed January 6, 2024)
12. Bustillo, M., Zabala, A., Querejeta, I., Carton, J. I., Mentxaka, O., González-Pinto, A., García, S. M., Meana, J. J., Eguíluz, J. I., Segarra, R. (2018) Therapeutic drug monitoring of second-generation antipsychotics for the estimation of early drug effect in first-episode psychosis: A cross-sectional assessment. Ther. Drug Monit. 40(2), 257–267. <https://doi.org/10.1097/FTD.0000000000000480>
13. Caccia, S., Pasina, L., Nobili, A. (2012) Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr. Dis. Treat. 8, 155–168. <https://doi.org/10.2147/NDT.S18059>
14. Cariprazine (2017) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/documents/product-information/reagila-epar-product-information_en.pdf (Accessed January 6, 2024)
15. Carrascal-Laso, L., Isidoro-García, M., Ramos-Gallego, I., Franco-Martín, M. (2021) Review: Influence of the CYP450 genetic variation on the treatment of psychotic disorders. J. Clin. Med. 10(18), 4275. <https://doi.org/10.3390/jcm10184275>
16. Castberg, I., Skogvoll, E., Spigset, O. (2007) Quetiapine and drug interactions. J. Clin. Psychiatry 68(10), 1540–1545. <https://doi.org/10.4088/JCP.v68n1011>
17. Citrome, L. (2012a) Lurasidone in schizophrenia: New information about dosage and place in therapy. Adv. Ther. 29(10), 815–825. <https://doi.org/10.1007/s12325-012-0052-6>
18. Citrome, L. (2012b) Oral paliperidone extended-release: Chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin. Drug Metab. Toxicol. 8(7), 873–888. <https://doi.org/10.1517/17425255.2012.693160>
19. Citrome, L. (2013) A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: An evidence-based medicine approach. CNS Drugs 27(11), 879–911. <https://doi.org/10.1007/s40263-013-0105-7>
20. Citrome, L., Stauffer, V. L., Chen, L., Kinon, B. J., Kurtz, D. L., Jacobson, J. G., Bergstrom, R. F. (2009) Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration. J. Clin. Psychopharmacol. 29(3), 278–283. <https://doi.org/10.1097/JCP.0b013e3181a289cb>
21. Clark, S., Warren, N., Kim, G., Jankowiak, D., Schubert, K. O., Kisely, S., Forrester, T., Baune, B. T., Siskind, D. (2018) Elevated clozapine levels associated with infection: A systematic review. Schizophr. Res. 192, 50–56. <https://doi.org/10.1016/j.schres.2017.03.045>
22. Clozapine (2002) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/leponex (Accessed January 6, 2024)
23. Correll, C. U., Agid, O., Crespo-Facorro, B., De Bartolomeis, A., Fagiolini, A., Seppälä, N., Howes, O. (2022) A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs 36(7), 659–679. <https://doi.org/10.1007/s40263-022-00932-2>
24. Darby, J., Pasta, D. J., Wilson, M. G., Herbert, J. S. (2008) Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: A clinical, two-group, naturalistic study. Clin. Drug Investig. 28(9), 553–564. <https://doi.org/10.2165/00044011-200828090-00002>
25. Dettling, M., Sachse, C., Brockmöller, J., Schley, J., Müller-Oerlinghausen, B., Pickersgill, I., Rolfs, A., Schaub, R. T., Schmider, J. (2000) Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology (Berl.) 152(1), 80–86. <https://doi.org/10.1007/s002130000503>
26. DeVane, C. L., Nemeroff, C. B. (2001) Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin. Pharmacokinet. 40(7), 509–522. <https://doi.org/10.2165/00003088-200140070-00003>
27. Eap, C. B., Bender, S., Sirot, E. J., Cucchia, G., Jonzier-Perey, M., Baumann, P., Allorge, D., Broly, F. (2004) Nonresponse to clozapine and ultrarapid CYP1A2 activity. J. Clin. Psychopharmacol. 24(2), 214–219. <https://doi.org/10.1097/01.jcp.0000116646.91923.2f>
28. Erickson-Ridout, K. K., Zhu, J., Lazarus, P. (2011) Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet. Genomics 21(9), 539–551. <https://doi.org/10.1097/FPC.0b013e328348c76b>
29. Erickson-Ridout, K. K., Sun, D., Lazarus, P. (2012) Glucuronidation of the second-generation antipsychotic clozapine, and its active metabolite N-desmethylclozapine. xPotential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms. Pharmacogenet. Genomics 22(8), 561–576. <https://doi.org/10.1097/FPC.0b013e328354026b>
30. Fabrazzo, M., La Pia, S., Monteleone, P., Esposito, G., Pinto, A., De Simone, L., Bencivenga, R., Maj, M. (2002) Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 27(6), 1050–1055. <https://doi.org/10.1016/S0893-133X(02)00319-6>
31. Fellows, L. M., Ahmad, F., Castle, D., Dusci, L. J., Bulsara, M., Ilett, K. F. (2003) Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Ther. Drug Monit. 25(6), 682–689. <https://doi.org/10.1097/00007691-200312000-00006>
32. Feng, Y., Pollock, B. G., Coley, K. C., Marder, S. R., Miller, D. D., Kirshner, M. A., Aravagiri, M., Schneider, L. S., Bies, R. R. (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br. J. Clin. Pharmacol. 66(5), 629–639. <https://doi.org/10.1111/j.1365-2125.2008.03276.x>
33. Frankel, J. S., Schwartz, T. L. (2017) Brexpiprazole and cariprazine: Distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther. Adv. Psychopharmacol. 7(1), 29–41. <https://doi.org/10.1177/2045125316672136>
34. Gee, S., Taylor, D., Shergill, S. S., Flanagan, R. J., MacCabe, J. H. (2017) Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Ther. Adv. Psychopharmacol. 7(2), 79–83. <https://doi.org/10.1177/2045125316677027>
35. Gettu, N., Saadabadi, A. (2023) Aripiprazole. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK547739/ (Accessed January 6, 2024)
36. Greenberg, W. M., Citrome, L. (2016) Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: A systematic review of the published literature. Clin. Pharmacokinet. 56(5), 493–503. <https://doi.org/10.1007/s40262-016-0465-5>
37. Gründer, G., Fellows, C., Janouschek, H., Veselinović, T., Boy, C., Bröcheler, A., Kirschbaum, K. M., Hellmann, S., Spreckelmeyer, K. M., Hiemke, C., Rösch, F., Schaefer, W. M., Vernaleken, I. (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am. J. Psychiatry 165(8), 988–995. <https://doi.org/10.1176/appi.ajp.2008.07101574>
38. Gründer, G., Hiemke, C., Paulzen, M., Veselinovic, T., Vernaleken, I. (2011) Therapeutic plasma concentrations of antidepressants and antipsychotics: Lessons from PET imaging. Pharmacopsychiatry 44(06), 236–248.
39. Grundmann, M., Kacirova, I., Urinovska, R. (2014) Therapeutic drug monitoring of atypical antipsychotic drugs. Acta Pharm. 64(4), 387–401. <https://doi.org/10.2478/acph-2014-0036>
40. Handley, S. A., Bowskill, S., Patel, M. X., Flanagan, R. J. (2013) Plasma quetiapine in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 2000–2011. Ther. Adv. Psychopharmacol. 3(3), 129–137. <https://doi.org/10.1177/2045125312470677>
41. Harrison, T. S., Perry, C. M. (2004) Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 64(15), 1715–1736. <https://doi.org/10.2165/00003495-200464150-00010>
42. Hart, X. M., Hiemke, C., Eichentopf, L., Lense, X., Clement, H. W., Conca, A., Faltraco, F., De Florio, V., Grüner, J., Havemann-Reinecke, U., Molden, E., Paulzen, M., Schoretsanitis, G., Riemer, T., Gründer, G. (2022) Therapeutic reference range for aripiprazole in schizophrenia revised: A systematic review and metaanalysis. Psychopharmacology (Berl.) 239(11), 3377–3391. <https://doi.org/10.1007/s00213-022-06233-2>
43. Hasselstrøm, J. B., Linnet, K. (2004) Quetiapine serum concentrations in psychiatric patients: The influence of comedication. Ther. Drug Monit. 26(5), 486–491. <https://doi.org/10.1097/00007691-200410000-00005>
44. Hendset, M., Hermann, M., Lunde, H., Refsum, H., Molden, E. (2007) Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur. J. Clin. Pharmacol. 63(12), 1147–1151. <https://doi.org/10.1007/s00228-007-0373-6>
45. Hiemke, C., Bergemann, N., Clement, H.-W., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., Gründer, G., Haen, E., Havemann-Reinecke, U., Hefner, G., Helmer, R., Janssen, G. M. E., Jaquenoud, E., Laux, G., Messer, T., Mößner, R., Müller, M. J., Paulzen, M., Pfuhlmann, B., Riederer, P., Saria, A., Schoppek, B., Schoretsanitis, G., Schwarz, M., Gracia, M. S., Stegmann, B., Steimer, W., Stingl, J. C., Uhr, M., Ulrich, S., Unterecker, S., Waschgler, R., Zernig, G., Zurek, G., Baumann, P. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51(01/02), 9–62.
46. Horvitz-Lennon, M., Mattke, S., Predmore, Z., Howes, O. (2017) The role of antipsychotic plasma levels in the treatment of schizophrenia. Am. J. Psychiatry 174(5), 421–426. <https://doi.org/10.1176/appi.ajp.2016.16040402>
47. Ishigooka, J., Iwashita, S., Higashi, K., Liew, E. L., Tadori, Y. (2018) Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. J. Clin. Pharmacol. 58(1), 74–80. <https://doi.org/10.1002/jcph.979>
48. Jovanović, M., Vučićević, K., Miljković, B. (2020) Understanding variability in the pharmacokinetics of atypical antipsychotics – Focus on clozapine, olanzapine and aripiprazole population models. Drug Metab. Rev. 52(1), 1–18. <https://doi.org/10.1080/03602532.2020.1717517>
49. Jukic, M., Smith, R. L., Haslemo, T., Molden, E., Ingelman-Sundberg, M. (2019) Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: A retrospective, cohort study. Lancet Psychiatry 6(5), 418–426. <https://doi.org/10.1016/S2215-0366(19)30088-4>
50. Khan, A. Y., Preskorn, S. (2005) Examining concentration-dependent toxicity of clozapine: Role of therapeutic drug monitoring. J. Psychiatr. Pract. 11(5), 289–301. <https://doi.org/10.1097/00131746-200509000-00003>
51. Kim, D. D., Barr, A. M., De Vere White, R., Honer, W. G., Procyshyn, R. M. (2019) Clozapine-induced obsessive-compulsive symptoms: Mechanisms and treatment. J. Psychiatry Neurosci. 44(1), 71–72. <https://doi.org/10.1503/jpn.180087>
52. Kim, J. R., Seo, H. B., Cho, J. Y., Kang, D. H., Kim, Y. K., Bahk, W.-J., Yu, K., Shin, S. G., Kwon, J. S., Jang, I. J. (2008) Population pharmacokinetic modelling of aripiprazole, and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br. J. Clin. Pharmacol. 66(6), 802–810. <https://doi.org/10.1111/j.1365-2125.2008.03223.x>
53. Kirschbaum, K. M., Müller, M. J., Zernig, G., Saria, A., Mobascher, A., Malevani, J., Hiemke, C. (2005) Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin. Chem. 51(9), 1718–1721. <https://doi.org/10.1373/clinchem.2005.049809>
54. Kirschbaum, K. M., Müller, M. J., Malevani, J., Mobascher, A., Burchardt, C., Piel, M., Hiemke, C. (2008) Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J. Biol. Psychiatry 9(3), 212–218. <https://doi.org/10.1080/15622970701361255>
55. Kitchen, D., Till, A., Xavier, P. (2021) Routine clozapine assay monitoring to improve the management of treatment-resistant schizophrenia. BJPsych Bull. 46(5), 267–270. <https://doi.org/10.1192/bjb.2021.36>
56. Korell, J., Green, B., Remmerie, B., Vermeulen, A. (2017) Determination of plasma concentration reference ranges for risperidone and paliperidone. CPT Pharmacometrics Syst. Pharmacol. 6(9), 589–595. <https://doi.org/10.1002/psp4.12217>
57. Krivoy, A., Whiskey, E., Webb-Wilson, H., Joyce, D. W., Tracy, D. K., Gaughran, F., MacCabe, J. H., Shergill, S. S. (2021) Outcomes in treatment-resistant schizophrenia: Symptoms, function and clozapine plasma concentrations. Ther. Adv. Psychopharmacol. 11, 204512532110371. <https://doi.org/10.1177/20451253211037179>
58. Kroon, L. A. (2007) Drug interactions with smoking. Am. J. Health Syst. Pharm. 64(18), 1917–1921. <https://doi.org/10.2146/ajhp060414>
59. Lane, H., Guo, S.-C., Hwang, T., Chen, Y.-S., Cheng, J. J. S., Lee, Y.-C., Hong, C., Hwu, H.-G., Chang, W. (2002) Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: A pilot study. J. Clin. Psychopharmacol. 22(5), 530–532. <https://doi.org/10.1097/00004714-200210000-00019>
60. Lin, S., Su, S.-F., Pan, C. (2006) Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther. Drug Monit. 28(3), 303–307. <https://doi.org/10.1097/01.ftd.0000211801.66569.80>
61. Liu, H.-Y., Hwang, T., Tsai, I., Kuo, C. (2015) Use of high-conductivity sample solution with sweeping-micellar electrokinetic capillary chromatography for trace-level quantification of paliperidone in human plasma. Electrophoresis 36(4), 534–542. <https://doi.org/10.1002/elps.201400230>
62. Locatelli, I., Kastelic, M., Koprivšek, J., Kores-Plesničar, B., Mrhar, A., Dolžan, V., Grabnar, I. (2010) A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur. J. Pharm. Sci. 41(2), 289–298. <https://doi.org/10.1016/j.ejps.2010.06.016>
63. Lopez, L. V., Kane, J. M. (2013) Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature. Schizophr. Res. 147(2–3), 368–374. <https://doi.org/10.1016/j.schres.2013.04.002>
64. Lu, J., Yang, Y., Lü, J., Wang, Z., He, Y., Yan, Y., Fu, K., Jiang, W., Xu, Y., Wu, R., Liu, W., Zhao, J. (2021) Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone. BMC Psychiatry 21(1), 70. <https://doi.org/10.1186/s12888-020-03034-9>
65. Lurasidone (2018) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/documents/product-information/latuda-epar-product-information_en.pdf (Accessed January 6, 2024)
66. Maan, J. S., Ershadi, M., Khan, I., Saadabadi, A. (2023) Quetiapine. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459145/ (Accessed January 6, 2024)
67. Markovic, M., Gallipani, A., Patel, K. H., Maroney, M. (2017) Brexpiprazole. Ann. Pharmacother. 51(4), 315–322. <https://doi.org/10.1177/1060028016678262>
68. Mauri, M. C., Laini, V., Boscati, L., Rudelli, R., Salvi, V., Orlandi, R., Papa, P. (2001) Long-term treatment of chronic schizophrenia with risperidone: A study with plasma levels. Eur. Psychiatry 16(1), 57–63. <https://doi.org/10.1016/S0924-9338(00)00536-8>
69. Mauri, M. C., Steinhilber, C., Marino, R., Invernizzi, E., Fiorentini, A., Cerveri, G., Baldi, M., Barale, F. (2005) Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur. Psychiatry 20(1), 55–60. <https://doi.org/10.1016/j.eurpsy.2004.09.009>
70. Mauri, M. C., Volonteri, L. S., Colasanti, A., Fiorentini, A., De Gaspari, I. F., Bareggi, S. R. (2007) Clinical pharmacokinetics of atypical antipsychotics. Clin. Pharmacokinet. 46(5), 359–388. <https://doi.org/10.2165/00003088-200746050-00001>
71. Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., Altamura, A. C. (2014) Clinical pharmacology of atypical antipsychotics: An update. EXCLI J. 13(13), 1163–1191.
72. Mauri, M. C., Paletta, S., Di Pace, C., Reggiori, A., Rovera, C., Fiorentini, A., Altamura, C. (2017) Paliperidone long-acting plasma level monitoring and a new method of evaluation of clinical stability. Pharmacopsychiatry 50(4), 145–151.
73. Mauri, M. C., Paletta, S., Di Pace, C., Reggiori, A., Cirnigliaro, G., Valli, I., Altamura, A. C. (2018) Clinical pharmacokinetics of atypical antipsychotics: An update. Clin. Pharmacokinet. 57(12), 1493–1528. <https://doi.org/10.1007/s40262-018-0664-3>
74. McCutcheon, R., Beck, K., D’Ambrosio, E., Donocik, J., Gobjila, C., Jauhar, S., Kaar, S., Pillinger, T., Marques, T. R., Rogdaki, M., Howes, O. (2018) Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr. Scand. 137(1), 39–46. <https://doi.org/10.1111/acps.12825>
75. McGrath, J. J., Saha, S., Chant, D., Welham, J. (2008) Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30(1), 67–76. <https://doi.org/10.1093/epirev/mxn001>
76. Melnik, T., Soares, B., Puga, M. E., Atallah, A. N. (2010) Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: Overview of systematic reviews. Sao Paulo Med. J. 128(3), 141–166. <https://doi.org/10.1590/S1516-31802010000300007>
77. Molden, E., Lunde, H., Lunder, N., Refsum, H. (2006) Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther. Drug Monit. 28(6), 744–749. <https://doi.org/10.1097/01.ftd.0000249944.42859.bf>
78. Moresco, R. M., Cavallaro, R., Messa, C., Bravi, D., Gobbo, C., Galli, L., Lucignani, G., Colombo, C., Rizzo, G., Velona, I., Smeraldi, E., Fazio, F. (2004) Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J. Psychopharmacol. 18(3), 355–365. <https://doi.org/10.1177/026988110401800306>
79. Moschny, N., Hefner, G., Grohmann, R., Eckermann, G., Maier, H., Seifert, J., Heck, J., Francis, F., Bleich, S., Toto, S. (2021) Therapeutic drug monitoring of second- and third-generation antipsychotic drugs – Influence of smoking behavior and inflammation on pharmacokinetics. Pharmaceuticals (Basel) 14(6), 514. <https://doi.org/10.3390/ph14060514>
80. Muly, E. C., Votaw, J. R., Ritchie, J. C., Howell, L. L. (2012) Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J. Pharmacol. Exp. Ther. 341(1), 81–89. <https://doi.org/10.1124/jpet.111.189076>
81. Nakamura, T., Kubota, T., Iwakaji, A., Imada, M., Kapás, M., Morio, Y. (2016) Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des. Devel. Ther. 10, 327–338. <https://doi.org/10.2147/DDDT.S95100>
82. Nazirizadeh, Y., Vogel, F., Bader, W., Haen, E., Pfuhlmann, B., Gründer, G., Paulzen, M., Schwarz, M. J., Zernig, G., Hiemke, C. (2010) Serum concentrations of paliperidone versus risperidone and clinical effects. Eur. J. Clin. Pharmacol. 66(8), 797–803. <https://doi.org/10.1007/s00228-010-0812-7>
83. Nofziger, C., Turner, A., Sangkuhl, K., Whirl-Carrillo, M., Agúndez, J. A. G., Black, J. L., Dunnenberger, H. M., Ruaño, G., Kennedy, M. A., Phillips, M., Hachad, H., Klein, T. E., Gaedigk, A. (2020) PharmVaR GeneFocus: CYP2D6. Clin. Pharmacol. Ther. 107(1), 154–170. <https://doi.org/10.1002/cpt.1643>
84. Olanzapine (2006) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/documents/product-information/zyprexa-epar-product-information_en.pdf (Accessed January 6, 2024)
85. Paliperidone (2021) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/invega (Accessed January 6, 2024)
86. Patteet, L., Haufroid, V., Maudens, K. E., Sabbe, B., Morrens, M., Neels, H. (2015) Genotype and co-medication dependent CYP2D6 metabolic activity: Effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur. J. Clin. Pharmacol. 72(2), 175–184.
87. Paulzen, M., Haen, E., Stegmann, B., Unterecker, S., Hiemke, C., Gründer, G., Schoretsanitis, G. (2016) Clinical response in a risperidone-medicated naturalistic sample: Patients’ characteristics and dose-dependent pharmacokinetic patterns. Eur. Arch. Psychiatry Clin. Neurosci. 267(4), 325–333. <https://doi.org/10.1007/s00406-016-0736-z>
88. Perry, P. J., Lund, B. C., Sanger, T. M., Beasley, C. M. (2001) Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine Trial. J. Clin. Psychopharmacol. 21(1), 14–20. <https://doi.org/10.1097/00004714-200102000-00004>
89. Puangpetch, A., Vanwong, N., Nuntamool, N., Hongkaew, Y., Chamnanphon, M., Sukasem, C. (2016) CYP2D6 polymorphisms and their influence on risperidone treatment. Pharm. Pers. Med. 9, 131–147.
90. Quetiapine (2014) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/seroquel-seroquel-xr-and-associated-names (Accessed January 6, 2024)
91. Remington, G., Mamo, D., Labelle, A., Reiss, J., Shammi, C., Mannaert, E., Mann, S., Kapur, S. (2006) A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am. J. Psychiatry 163(3), 396–401. <https://doi.org/10.1176/appi.ajp.163.3.396>
92. Riedel, M., Schwarz, M. J., Strassnig, M., Spellmann, I., Müller-Arends, A., Weber, K. S. C., Zach, J., Müller, N., Möller, H. (2004) Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci. 255(4), 261–268. <https://doi.org/10.1007/s00406-004-0556-4>
93. Risperidone (2008) Summary of Product Characteristics. Committee for Medicinal Products for Human Use. European Medicines Agency. European public assessment report. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/risperdal (Accessed January 6, 2024)
94. Samanaite, R., Gillespie, A., Sendt, K.-V., McQueen, G., MacCabe, J. H., Egerton, A. (2018) Biological predictors of clozapine response: A systematic review. Front. Psychiatry 9, 327. <https://doi.org/10.3389/fpsyt.2018.00327>
95. Schoretsanitis, G., Stegmann, B., Hiemke, C., Gründer, G., Schruers, K., Walther, S., Lammertz, S. E., Haen, E., Paulzen, M. (2016) Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur. J. Clin. Pharmacol. 72(9), 1091–1098. <https://doi.org/10.1007/s00228-016-2085-2>
96. Schoretsanitis, G., Kane, J. M., Correll, C. U., Marder, S. R., Citrome, L., Newcomer, J. W., Robinson, D. G., Goff, D. C., Kelly, D. L., Freudenreich, O., Piacentino, D., Paulzen, M., Conca, A., Zernig, G., Haen, E., Baumann, P., Hiemke, C., Gründer, G.; American Society of Clinical Psychopharmacology; Pharmakopsychiatrie TTDMTFOTAFNU (2020) Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J. Clin. Psychiatry 81(3), 19cs13169. <https://doi.org/10.4088/JCP.19cs13169>
97. Schoretsanitis, G., Yağcıoğlu, A. E. A., Ruan, C., Eap, C. B., Molden, E., Baptista, T., Clark, S., Fernández-Egea, E., Kim, S. H., Lane, H. Y., Leung, J. G., Amigo, O. M., Motuca, M., Olmos, I., Every-Palmer, S., Procyshyn, R. M., Rohde, C., Suhas, S., Schulte, P. F. J., Spina, E., Takeuchi, H., Verdoux, H., Correll, C. U., de Leon, J. (2023) Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition. Schizophr. Res. (Epub ahead of print)
98. Seto, K., Dumontet, J., Ensom, M. H. H. (2011) Risperidone in schizophrenia: Is there a role for therapeutic drug monitoring? Ther. Drug Monit. 33(3), 275–283. <https://doi.org/10.1097/FTD.0b013e3182126d83>
99. Skokou, M., Karavia, E. A., Drakou, Z., Konstantinopoulou, V., Kavakioti, C.-A., Gourzis, P., Kypreos, K. E., Andreopoulou, O. (2022) Adverse drug reactions in relation to clozapine plasma levels: A systematic review. Pharmaceuticals (Basel) 15(7), 817. <https://doi.org/10.3390/ph15070817>
100. Sparshatt, A., Jones, S., Taylor, D. (2008) Quetiapine: Dose-response relationship in schizophrenia. CNS Drugs 22(1), 49–68. <https://doi.org/10.2165/00023210-200822010-00004>
101. Sparshatt, A., Taylor, D., Patel, M. X., Kapur, S. (2010) A systematic review of aripiprazole – Dose, plasma concentration, receptor occupancy, and response: Implications for therapeutic drug monitoring. J. Clin. Psychiatry 71(11), 1447–1456. <https://doi.org/10.4088/JCP.09r05060gre>
102. Sparshatt, A., Taylor, D., Patel, M. X., Kapur, S. (2011) Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: A review. J. Clin. Psychiatry 72(08), 1108–1123. <https://doi.org/10.4088/JCP.09r05739yel>
103. Spina, E., de Leon, J. (2007) Metabolic drug interactions with newer antipsychotics: A comparative review. Basic Clin. Pharmacol. Toxicol. 100(1), 4–22. <https://doi.org/10.1111/j.1742-7843.2007.00017.x>
104. Spina, E., Avenoso, A., Facciolà, G., Scordo, M. G., Ancione, M., Madia, A. G., Ventimiglia, A., Perucca, E. (2000) Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl.) 148(1), 83–89. <https://doi.org/10.1007/s002130050028>
105. Spina, E., Avenoso, A., Facciolà, G., Salemi, M., Scordo, M. G., Ancione, M., Madia, A. G., Perucca, E. (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl.) 153(2), 238–243. <https://doi.org/10.1007/s002130000576>
106. Stahl, S. M. (2014) Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge University Press, Cambridge.
107. Steen, N. E., Aas, M., Simonsen, C., Dieset, I., Tesli, M., Nerhus, M., Gardsjord, E. S., Mørch, R. H., Agartz, I., Melle, I., Ueland, T., Spigset, O., Andreassen, O. A. (2016) Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders. World J. Biol. Psychiatry 18(6), 471–482. <https://doi.org/10.1080/15622975.2016.1245441>
108. Suzuki, H., Gen, K., Otomo, M., Inoue, Y., Hibino, H., Mikami, A., Matsumoto, H., Mikami, K. (2014a) Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia. Hum. Psychopharmacol. 29(3), 244–250. <https://doi.org/10.1002/hup.2393>
109. Suzuki, T., Mihara, K., Nakamura, A., Kagawa, S., Nagai, G., Nemoto, K., Kondo, T. (2014b) Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther. Drug Monit. 36(5), 651–655. <https://doi.org/10.1097/FTD.0000000000000070>
110. Takano, A., Suhara, T., Ikoma, Y., Yasuno, F., Maeda, J., Ichimiya, T., Sudo, Y., Inoue, M., Okubo, Y. (2004) Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int. J. Neuropsychopharmacol. 7(1), 19–26. <https://doi.org/10.1017/S1461145703003912>
111. Taylor, D. M., Barnes, T. R. E., Young, A. H. (2021) The Maudsley Prescribing Guidelines in Psychiatry. John Wiley and Sons, Hoboken.
112. Thomas, K., Saadabadi, A. (2023) Olanzapine. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532903/ (Accessed January 6, 2024)
113. Tralongo, F., Konecki, C., Féliu, C., Kaladjian, A., Djerada, Z. (2023) Association between clozapine plasma concentrations and treatment response: A systematic review, meta-analysis and individual participant data meta-analysis. Clin. Pharmacokinet. 62(6), 807–818. <https://doi.org/10.1007/s40262-023-01247-1>
114. Tsuda, Y., Saruwatari, J., Yasui-Furukori, N. (2014) Meta-analysis: The effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open 4(3), e004216. <https://doi.org/10.1136/bmjopen-2013-004216>
115. Urban, A. E., Cubała, W. J. (2017) Therapeutic drug monitoring of atypical antipsychotics. Psychiatr. Pol. 51(6), 1059–1077. <https://doi.org/10.12740/PP/65307>
116. Urichuk, L., Prior, T. I., Dursun, S., Baker, G. B. (2008) Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 9(5), 410–418. <https://doi.org/10.2174/138920008784746373>
117. van der Weide, K., van der Weide, J. (2015) The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. J. Clin. Psychopharmacol. 34(2), 256–260. <https://doi.org/10.1097/JCP.0000000000000070>
118. Vandenberghe, F., Guidi, M., Choong, E., Von Gunten, A., Conus, P., Csajka, C., Eap, C. B. (2015) Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin. Pharmacokinet. 54(12), 1259–1272. <https://doi.org/10.1007/s40262-015-0289-8>
119. Vernaleken, I., Janouschek, H., Raptis, M., Hellmann, S., Veselinović, T., Bröcheler, A., Boy, C., Cumming, P., Hiemke, C., Rösch, F., Schäfer, W., Gründer, G. (2010) Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int. J. Neuropsychopharmacol. 13(07), 951–960. <https://doi.org/10.1017/S1461145710000374>
120. Wong, J., Leung, S.-P., Mak, T., Ng, R. M. K., Chan, K. T., Cheung, H. H.-K., Choi, W., Lai, J. P. S., Tsang, A. W.-K. (2006) Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(2), 251–264. <https://doi.org/10.1016/j.pnpbp.2005.10.008>
121. Yasui-Furukori, N., Saito, M., Nakagami, T., Furukori, H., Suzuki, A., Kondo, T., Kaneko, S. (2009) Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J. Psychopharmacol. 24(7), 987–994. <https://doi.org/10.1177/0269881109104849>
122. Yokoi, F. (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27(2), 248–259. <https://doi.org/10.1016/S0893-133X(02)00304-4>
123. Yoshimura, R., Ueda, N., Nakamura, J. (2001) Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Neuropsychobiology 44(3), 129–133. <https://doi.org/10.1159/000054932>
124. Zhang, J., Malhotra, A. K. (2018) Recent progress in pharmacogenomics of antipsychotic drug response. Curr. Psychiatry Rep. 20(4), 24. <https://doi.org/10.1007/s11920-018-0886-y>
125. Zhang, X., Xiang, Q., Zhao, X., Ma, L., Chen, Y. (2018) Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis. J. Clin. Pharm. Ther. 44(2), 163–173. <https://doi.org/10.1111/jcpt.12780>
126. Zhou, Z., Li, X., Huai-Yan, P., Yu, X., Yang, M., Su, F.-L., Wang, F., Zhu, R., Deng, C., Lin, Q., Wang, C., Li, W.-B., Lin, S., Huan-De, L. (2006) Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol. Sin. 27(3), 381–386. <https://doi.org/10.1111/j.1745-7254.2006.00256.x>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive